The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials

BACKGROUND: Previous studies revealed that Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus anti-angiogenic agents had extensive anti-tumor activities. However, almost all studies on the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shubin, Mo, Wanying, Jiang, Wei, Zhou, Shaozhang, Gan, Haijie, Yu, Qitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442655/
https://www.ncbi.nlm.nih.gov/pubmed/37614237
http://dx.doi.org/10.3389/fimmu.2023.1218258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442655/
https://www.ncbi.nlm.nih.gov/pubmed/37614237
http://dx.doi.org/10.3389/fimmu.2023.1218258

Ejemplares similares